ClinicalTrials.Veeva

Menu
New Mexico Clinical Research and Osteoporosis Center | Albuquerque, NM logo

New Mexico Clinical Research and Osteoporosis Center | Albuquerque, NM

Research site

Site insights

Top conditions

Top treatments

Zoledronic Acid
MK-0616
PF-04950615
CC-93538
RN316
Tanezumab
ALX1-11
LY3090106
PF708
Teriparatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Mary Niles

Verified by this site

Active trials

7 of 54 total trials

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The m...

Active, not recruiting
Interstitial Cystitis
Bladder Pain Syndrome
Drug: Placebo
Drug: IW-3300 rectal foam

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Enlicitide Decanoate
Drug: Placebo

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs...

Active, not recruiting
Osteogenesis Imperfecta
Other: Placebo
Biological: Setrusumab

Trial sponsors

Pfizer logo
MannKind logo
Celgene logo
Merck Sharp & Dohme (MSD) logo
Shire logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Ironwood Pharmaceuticals logo
Lilly logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems